Lilly/PCS consent agreement approved by FTC; changes do not affect manufacturer/PBM relationship.
Executive Summary
LILLY/PCS CONSENT AGREEMENT RECEIVES FINAL APPROVAL FROM FTC with minor modifications that do not affect the relationship between Lilly and its pharmacy benefit management subsidiary PCS. The Federal Trade Commission voted 3-1 to adopt the consent agreement, which was provisionally accepted in November. The agreement stipulates that PCS must offer customers an open formulary chosen by an independent P&T committee and prohibits PCS from sharing proprietary information with Lilly ("The Pink Sheet" Nov. 7, 1994, p. 3).